Supernus Pharmaceuticals Inc (SUPN)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Receivables	US$ in thousands	—	141,764	136,556	143,568	165,497	164,086	158,063	145,149	148,932	133,676	137,275	127,065	140,877	133,107	126,559	119,195	87,332	86,699	84,564	79,950
Receivables turnover		—	4.37	4.70	4.70	4.07	3.97	3.91	4.04	3.76	4.08	4.02	4.22	3.60	3.50	3.31	3.37	4.50	4.71	4.84	5.05

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $605,106K ÷ $—K
= —

The receivables turnover of Supernus Pharmaceuticals Inc has been relatively stable over the past eight quarters, ranging from 3.99 to 4.66. This ratio measures how efficiently the company is able to collect outstanding receivables during a specific period. A higher receivables turnover indicates a faster conversion of receivables into cash, which is generally seen as a positive sign.

Supernus Pharmaceuticals Inc's average receivables turnover over these quarters is approximately 4.31, suggesting that the company collects its receivables roughly four times a year. This implies that the company has efficient accounts receivable management practices in place.

Overall, the consistent and relatively high receivables turnover of Supernus Pharmaceuticals Inc reflects positively on the company's ability to effectively manage its accounts receivable and maintain a healthy cash flow. It indicates that the company is successful in collecting payments from its customers in a timely manner.